In December 2015, CV Sciences acquired CanX Inc., a pre-clinical drug development company focused on significant unmet medical needs. The initial drug candidate (CVSI-007) is a chewing gum containing nicotine and synthetic CBD to support cessation of smokeless tobacco use and addiction. The product is in the pre-clinical stage.
Multi-billion market opportunity presented by initial drug candidate (CVSI-007), a proprietary chewing gum that combines synthetic CBD and nicotine to effectively treat smokeless tobacco addiction.
etc., etc, . . . ad nauseam
CV Sciences has been dangling this CHEWING GUM in front of investors for 5 years !
AI
